Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Thursday

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Syros Pharmaceuticals to post earnings of ($0.67) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.09. On average, analysts expect Syros Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Stock Performance

NASDAQ:SYRS traded down $0.07 during trading hours on Friday, hitting $2.00. 257,219 shares of the company traded hands, compared to its average volume of 234,584. The company has a current ratio of 3.46, a quick ratio of 3.46 and a debt-to-equity ratio of 1.97. The stock has a market capitalization of $53.46 million, a price-to-earnings ratio of -0.41 and a beta of 1.59. The firm has a 50-day moving average of $1.84 and a 200 day moving average of $4.10. Syros Pharmaceuticals has a twelve month low of $1.43 and a twelve month high of $8.17.

Analyst Upgrades and Downgrades

A number of analysts have commented on SYRS shares. JMP Securities reduced their price objective on Syros Pharmaceuticals from $12.00 to $4.00 and set a "market outperform" rating for the company in a research report on Tuesday, August 13th. HC Wainwright decreased their price target on shares of Syros Pharmaceuticals from $15.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. Piper Sandler reaffirmed an "overweight" rating and set a $5.00 price objective (down from $13.00) on shares of Syros Pharmaceuticals in a report on Tuesday, August 13th. Finally, StockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Tuesday, October 15th.

Insider Buying and Selling

In other news, CFO Jason Haas bought 35,363 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was bought at an average price of $1.55 per share, for a total transaction of $54,812.65. Following the completion of the purchase, the chief financial officer now owns 59,915 shares of the company's stock, valued at approximately $92,868.25. The trade was a 100.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Jason Haas acquired 35,363 shares of the company's stock in a transaction on Tuesday, September 10th. The stock was purchased at an average cost of $1.55 per share, with a total value of $54,812.65. Following the acquisition, the chief financial officer now owns 59,915 shares of the company's stock, valued at $92,868.25. This trade represents a 100.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Conley Chee acquired 50,000 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was acquired at an average cost of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the purchase, the chief executive officer now owns 72,504 shares of the company's stock, valued at approximately $109,481.04. The trade was a 200.00 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 130,707 shares of company stock worth $206,491 in the last quarter. 12.26% of the stock is owned by corporate insiders.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.